DUBLIN--(BUSINESS WIRE)--The "Global Acromegaly and Gigantism Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The global acromegaly and gigantism drugs market to grow at a CAGR of 3.03% during the period 2018-2022.
Global Acromegaly and Gigantism Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The latest trend gaining momentum in the market is growing popularity of drugs over surgeries. Although pharmacological therapies for acromegaly treatment have been there for more than a decade, the demand from individuals for these non-surgical options is increasing on a regular basis. The prime reason for the shift in choice can be attributed to low success rates of acromegaly surgeries.
According to the report, one of the major drivers for this market is Strong pipeline. The presence of a large number of molecules in pipeline represents significant opportunities for market growth. Around 42.86% of the total pipeline molecules for acromegaly and gigantism are in Phase III stage of development and are expected to be launched during the forecast period. Companies are working toward the development of drugs that cater to the unmet medical needs for this condition.
For instance, octreotide capsules by Chiasma and Pasireotide long-acting release (LAR) by Novartis for individuals with acromegaly who are inadequately treated with somatostatin analogs, and combination therapy of lanreotide autogel and pegvisomant by Ipsen are in Phase III stage of development for the treatment of acromegaly.
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Market Landscape
Part 06: Market Sizing
Part 07: Five Forces Analysis
Part 08: Pipeline Analysis
Part 09: Market Segmentation By Drug Class
Part 10: Customer Landscape
Part 11: Regional Landscape
Part 12: Decision Framework
Part 13: Drivers And Challenges
Part 14: Market Trends
Part 15: Vendor Landscape
Part 16: Vendor Analysis
Part 17: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/clm6zm/global_acromegaly?w=4